Please use this identifier to cite or link to this item: https://hdl.handle.net/1/254
Title: A randomised, cross-over study comparing injection site pain with subcutaneous Epoetin Beta and subcutaneous Darbepoetin Alfa in patients with chronic kidney disease
Authors: Roger, Simon D ;Suranyi, Michael ;Walker, Rowan ;Disney, Alex ;Isbel, Nicole M ;Kairaitis, Lukas ;Pollock, Carol ;Brown, Fiona G ;Chow, J.;Truman, Matt ;Ulyate, Kellie 
Issue Date: Aug-2008
Source: Volume 24, Issue 8, pp. 2181-2187
Journal title: Current Medical Research and Opinion
Abstract: OBJECTIVE: To compare injection site pain of subcutaneous (sc) epoetin beta and darbepoetin alfa in adult patients with chronic kidney disease. RESEARCH DESIGN AND METHODS: This was a multi-centre, randomised, two-arm, single-blind, cross-over study. Patients were randomised to receive weekly sc darbepoetin alfa 30 mug or weekly sc epoetin beta 6000 IU for 2 weeks and were then crossed over to the alternative treatment for 2 weeks. Injection site pain was assessed using a 10 cm ungraduated visual analogue scale (0 = no pain, 10 = worst pain) and a six-point verbal rating scale. Patient preference for treatment was also assessed. TRIAL REGISTRATION: http://clinicaltrials. gov/(NCT00377481). RESULTS: All randomised patients (N = 48) completed the study. The sample comprised 29 chronic kidney disease patients (Stage 3 or Stage 4), 11 peritoneal dialysis patients and 8 renal transplant patients. Patients perceived significantly less pain with epoetin beta than darbepoetin alfa, using the visual analogue scale (relative pain score = 2.75, darbepoetin alfa:epoetin beta, 95% CI: 1.85, 4.07; p < 0.0001) and the verbal rating scale (median: 0.5, 95% CI: 0.5, 1.0 vs. median: 1.5, 95% CI: 1.0, 2.0; p < 0.0001). Epoetin beta was preferred by significantly more patients (65%) than darbepoetin alfa (10%) (p < 0.001); 25% of patients reported no preference. CONCLUSIONS: Limitations included lack of an epoetin alfa comparator and limited blinding (patients were blinded to treatment, however, an unblinded nurse administered treatment). We show that sc injection of epoetin beta is significantly less painful than darbepoetin alfa and patient preference for epoetin beta confirms that the difference is clinically meaningful.
URI: https://elibrary.cclhd.health.nsw.gov.au/cclhdjspui/handle/1/254
DOI: 10.1185/03007990802240552
Pubmed: http://www.ncbi.nlm.nih.gov/pubmed/18565240
ISSN: 1473-4877
Publicaton type: Journal Article
Keywords: Kidney Disease
Drug Therapy
Study or Trial: Randomized Controlled Clinical Trial/Controlled Clinical Trial
Appears in Collections:Renal Medicine

Show full item record

Page view(s)

6
checked on Jan 29, 2023

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.